Mammoth Biosciences Stock

CRISPR-Based Disease Detection Platform

Sign up today and learn more about Mammoth Biosciences Stock

Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.



Notable Investors

Mayfield Fund


Brisbane CA, US

Total Funding


About Mammoth Biosciences Stock

Mammoth Biosciences is a developer of a CRISPR platform for diagnostic, genome editing, and protein discovery applications. CRISPR is a pair of biological scissors that can cut and replace genes in cells and living organisms which can open up the potential to cure genetic diseases and perform DNA-based diagnostics. Mammoth aims to discover new types of CRISPR systems that could be used to solve specific biological problems. 

Mammoth Biosciences was founded by Janice Chen in 2017 and is based in San Francisco, California. Notable investors include NFX, Mayfield Fund, and Decheng Capital.


Funding History

July 2018$18.1M
January 2020$7.4M
January 2020$36.8M
May 2020$748K
May 2020$44.4M
July 2021$100M
July 2021$50.0M


Chief Executive Officer

Trevor Martin

Chief Financial Officer

Elaine Sun


EquityZen does not have an affiliation with, formal relationship with, or endorsement from any companies featured above. This profile is based on publicly available information and is intended to be informative in nature.

Some data provided by Crunchbase

Join 630,000+ Investors and Shareholders

On our trusted digital marketplace for private companies

EquityZen Recognized As: